Charles Explorer logo
🇬🇧

Monitoring of the expensive pneumooncological tratment of the advanced non-small cell lung cancer (NSCLC) in the 1st line in the TULUNG registry in the Czech Republic

Publication at First Faculty of Medicine, Third Faculty of Medicine |
2012

Abstract

In this review article the analysis is presented of the tratment results in advanced non-small cell lung cancer patients treated in the Ist line by erlotinib, gefitinib, bevacizumab and pemetrexed in the Czech Republic.

Keywords